 leukemia Etoposide NSC complete response CR patients acute nonlymphocytic leukemia ANLL single agent Etoposide combination cytarabine daunorubicin amsacrine salvage consolidation therapies untreated ANLL patients years age days daunorubicin days drugs etoposide days CR consolidation courses attenuated eligible patients CR rate therapy CR rate therapy Remission duration median months months survival analysis patients years age prolonged remission median months months survival median months months regimen Hematologic toxicity similar regimens induction severe consolidation therapy Etoposide active ANLL prolongs remission induction therapy